Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy

May 12, 2020

Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights

May 11, 2020

Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

May 11, 2020

Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

May 11, 2020

Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers

May 08, 2020

Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

May 06, 2020

Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters

Apr 23, 2020

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab

Apr 21, 2020

Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency

Apr 20, 2020

Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights

Mar 30, 2020
RSS
  • Prev
    • 1...
    • 40
    • 41
    • 42
    • 43
    • 44
    • 45
    • 46
    • 47
    • 48
    • 49
    • ...71
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap